Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Biomarkers / Cramer 5-marker panel for ovarian cancer

Cramer 5-marker panel for ovarian cancer



QA State: Curated
Short Name:
HGNC Name:

The PLCO phase III specimens (test half) revealed marker panels produced only marginal improvement over CA 125 alone and, in some case, worse performance. Besides searching for new markers, some ways to improve detection might include: 1) Add epidemiologic variables, and 2) Add in prior markers values.

Panel Details


There are no datasets associated with this biomarker.


The following organs have data associated with this biomarker…



Phase: Three
QA State: Curated


The PLCO accepted the phase II reports (SPORE/EDRN/PLCO Ovarian Validation Study) and sent identical sets to the assay sites. Each set included sera for cases most proximate to the diagnosis of ovarian cancer which (on average) was about 9 months prior. There were 951 controls matched by age and timing of specimen collection including 475 general population controls, 238 with false positive CA 125, and 238 with family history of breast or ovarian cancer. 90 quality control specimens were also included. Investigators tested their markers and marker panels blinded to the status of the cases. PLCO unblinded the data in stages to allow further algorithm development.


This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at if you should have access to this biomarker.


No associated resources found.

2015 Steering Committee Meeting

The next EDRN Steering Committee Meeting will take place March 31st through April 2nd, 2015, in Atlanta, Georgia.

Announcement 02/12/2015

Please register for the 29th EDRN Steering Committee Meeting in Atlanta, GA from March 31-April 2, 2015. The registration page has information about booking hotel rooms and a draft agenda of the meeting.